Cargando…

Reengineering anthrax toxin protective antigen for improved receptor-specific protein delivery

BACKGROUND: To increase the size of the druggable proteome, it would be highly desirable to devise efficient methods to translocate designed binding proteins to the cytosol, as they could specifically target flat and hydrophobic protein-protein interfaces. If this could be done in a manner dependent...

Descripción completa

Detalles Bibliográficos
Autores principales: Becker, Lukas, Verdurmen, Wouter P. R., Plückthun, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427085/
https://www.ncbi.nlm.nih.gov/pubmed/32792013
http://dx.doi.org/10.1186/s12915-020-00827-y
_version_ 1783570821148573696
author Becker, Lukas
Verdurmen, Wouter P. R.
Plückthun, Andreas
author_facet Becker, Lukas
Verdurmen, Wouter P. R.
Plückthun, Andreas
author_sort Becker, Lukas
collection PubMed
description BACKGROUND: To increase the size of the druggable proteome, it would be highly desirable to devise efficient methods to translocate designed binding proteins to the cytosol, as they could specifically target flat and hydrophobic protein-protein interfaces. If this could be done in a manner dependent on a cell surface receptor, two layers of specificity would be obtained: one for the cell type and the other for the cytosolic target. Bacterial protein toxins have naturally evolved such systems. Anthrax toxin consists of a pore-forming translocation unit (protective antigen (PA)) and a separate protein payload. When engineering PA to ablate binding to its own receptor and instead binding to a receptor of choice, by fusing a designed ankyrin repeat protein (DARPin), uptake in new cell types can be achieved. RESULTS: Prepore-to-pore conversion of redirected PA already occurs at the cell surface, limiting the amount of PA that can be administered and thus limiting the amount of delivered payload. We hypothesized that the reason is a lack of a stabilizing interaction with wild-type PA receptor. We have now reengineered PA to incorporate the binding domain of the anthrax receptor CMG2, followed by a DARPin, binding to the receptor of choice. This construct is indeed stabilized, undergoes prepore-to-pore conversion only in late endosomes, can be administered to much higher concentrations without showing toxicity, and consequently delivers much higher amounts of payload to the cytosol. CONCLUSION: We believe that this reengineered system is an important step forward to addressing efficient cell-specific delivery of proteins to the cytosol.
format Online
Article
Text
id pubmed-7427085
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74270852020-08-16 Reengineering anthrax toxin protective antigen for improved receptor-specific protein delivery Becker, Lukas Verdurmen, Wouter P. R. Plückthun, Andreas BMC Biol Research Article BACKGROUND: To increase the size of the druggable proteome, it would be highly desirable to devise efficient methods to translocate designed binding proteins to the cytosol, as they could specifically target flat and hydrophobic protein-protein interfaces. If this could be done in a manner dependent on a cell surface receptor, two layers of specificity would be obtained: one for the cell type and the other for the cytosolic target. Bacterial protein toxins have naturally evolved such systems. Anthrax toxin consists of a pore-forming translocation unit (protective antigen (PA)) and a separate protein payload. When engineering PA to ablate binding to its own receptor and instead binding to a receptor of choice, by fusing a designed ankyrin repeat protein (DARPin), uptake in new cell types can be achieved. RESULTS: Prepore-to-pore conversion of redirected PA already occurs at the cell surface, limiting the amount of PA that can be administered and thus limiting the amount of delivered payload. We hypothesized that the reason is a lack of a stabilizing interaction with wild-type PA receptor. We have now reengineered PA to incorporate the binding domain of the anthrax receptor CMG2, followed by a DARPin, binding to the receptor of choice. This construct is indeed stabilized, undergoes prepore-to-pore conversion only in late endosomes, can be administered to much higher concentrations without showing toxicity, and consequently delivers much higher amounts of payload to the cytosol. CONCLUSION: We believe that this reengineered system is an important step forward to addressing efficient cell-specific delivery of proteins to the cytosol. BioMed Central 2020-08-13 /pmc/articles/PMC7427085/ /pubmed/32792013 http://dx.doi.org/10.1186/s12915-020-00827-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Becker, Lukas
Verdurmen, Wouter P. R.
Plückthun, Andreas
Reengineering anthrax toxin protective antigen for improved receptor-specific protein delivery
title Reengineering anthrax toxin protective antigen for improved receptor-specific protein delivery
title_full Reengineering anthrax toxin protective antigen for improved receptor-specific protein delivery
title_fullStr Reengineering anthrax toxin protective antigen for improved receptor-specific protein delivery
title_full_unstemmed Reengineering anthrax toxin protective antigen for improved receptor-specific protein delivery
title_short Reengineering anthrax toxin protective antigen for improved receptor-specific protein delivery
title_sort reengineering anthrax toxin protective antigen for improved receptor-specific protein delivery
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427085/
https://www.ncbi.nlm.nih.gov/pubmed/32792013
http://dx.doi.org/10.1186/s12915-020-00827-y
work_keys_str_mv AT beckerlukas reengineeringanthraxtoxinprotectiveantigenforimprovedreceptorspecificproteindelivery
AT verdurmenwouterpr reengineeringanthraxtoxinprotectiveantigenforimprovedreceptorspecificproteindelivery
AT pluckthunandreas reengineeringanthraxtoxinprotectiveantigenforimprovedreceptorspecificproteindelivery